CorMedix reports positive Phase III ReSPECT results for REZZAYO in fungal prophylaxis

CorMedix Inc.

Primary endpoint met: fungal-free survival at Day 90 was 60.7% for rezafungin vs 59.0% for standard regimen.
Rezafungin showed favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions.
Target supplemental NDA submission to FDA in 2H26 based on ReSPECT results.
CorMedix estimates US prophylaxis market opportunity for REZZAYO exceeds $2 billion.
Mundipharma sponsored the trial; holds ex-US rights; Melinta (CorMedix sub) distributes in US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.